KDM1A and acute myeloid leukemia: Indeed, the concept is supported by ongoing combination studies: for example, LSD1 inhibitors are now being tested with venetoclax (and hypomethylating agents) in frontline AML, reflecting the recognition that concurrent epigenetic and apoptotic targeting is highly potent [31].